See feature article below on: EXEL
About Broad Street Alerts:
Big opportunities in Small Cap’s
Broadstreetalerts.com recent profiles and track record, 157% in verifiable potential gains for our
members in December 2015 alone.
December 29th, 2015- (NASDAQ: INVT) opened $1.35/share hit a high midday of $2.82/share over 100%
in gains for our members.
December 15th, 2015-(NYSE-MKT: XXII) opened at $1.29 hit a high of $1.54 within 3 days for gains of
19% for our members.
December 2nd, 2015- (NASDAQ: TCCO) opened at $3.25 hit a high of $4.50 within 3 days for 38% gains
for our members.
February 14th, 2015 ETN report on 3x velocity shares Crude oil (NYSEMKT: UWTI) at $15.50/share up
nearly 100% in a little over a month for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to
see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and
verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest
of the small-cap newsletters as the best in business. We know with a large following comes a large
responsibility as we have everyone from institutional investors to the beginner following our profiled
securities in our newsletters. This is something we take very seriously always seeking small cap growth
companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our
VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your
Recently analysts working for a variety of stock market brokerages have changed their consensus ratings and price targets on shares of Exelixis, Inc. (NASDAQ:EXEL).
The most recent broker reports which have been released note that 2 analysts have a rating of “buy”, 1 analysts “outperform”, 2 analysts “hold”, 0 analysts “underperform” and 0 analysts “sell”.
Report on : EXEL
Recent analyst ratings and price targets:
03/01/2016 – Exelixis, Inc. had its “outperform” rating reiterated by analysts at Cowen.
01/19/2016 – Exelixis, Inc. was upgraded to “outperform” by analysts at Leerink Swann. They now have a USD 7 price target on the stock.
01/13/2016 – Exelixis, Inc. had its “outperform” rating reiterated by analysts at William Blair.
07/20/2015 – Exelixis, Inc. had its “neutral” rating reiterated by analysts at Piper Jaffray. They now have a USD 6 price target on the stock.
05/26/2015 – Exelixis, Inc. was downgraded to “hold” by analysts at Zacks.
05/14/2015 – Exelixis, Inc. had its “hold” rating reiterated by analysts at Stifel Nicolaus.
05/05/2014 – Exelixis, Inc. had its “neutral” rating reiterated by analysts at Credit Suisse. They now have a USD 4 price target on the stock.
05/02/2014 – Exelixis, Inc. had its “hold” rating reiterated by analysts at Jefferies. They now have a USD 4 price target on the stock.
01/21/2014 – Exelixis, Inc. had its “buy” rating reiterated by analysts at Maxim Group. They now have a USD 11 price target on the stock.
Exelixis, Inc. has a 50 day moving average of 4.07 and a 200 day moving average of 5.12. It has a 52-week low of 2.45 and a 52-week high of 6.81.
The share price of the company (NASDAQ:EXEL) was down -0.26%, with a high of 3.99 during the day and the volume of Exelixis, Inc. shares traded was 4546927.
Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States. The Company’s other programs include metastatic renal cell carcinoma (mRCC), a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL, a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888, a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).
Source: Share Trading